WuXi Biologics ISIN: KYG970081173 Forum: Aktien User: Summer.76

"Research Report" Nomura Cuts WuXi Biologics (02269.HK) Target Price to $95.75, Rated "Buy http://www.aastocks.com/tc/stocks/news/aafn-news/NOW.1189429/1

WuXi Biologics Launches First Commercial Drug Product Facility for Pre-Filled Syringes https://www.prnewswire.co.uk/news-releases/wuxi-biologics-launches-first-commercial-drug-product-facility-for-pre-filled-syringes-800736778.html • WuXi Biologics offers global partners high-efficiency and high-quality manufacturing services for clinical trial and commercial supply by increasing pre-filled syringes (PFS) capacity to 17 million units per year. • WuXi Biologics has established a global manufacturing network with 9 drug product facilities for vial and PFS in China and Germany, and is now one of the global leaders in drug product CDMO services. • Advanced single-use technology and automated equipment allow for decreasing risk of contamination. ...

Harding Loevner - WuXi Biologics: Sporting A 100x Forward Price-To-Earnings Multiple https://seekingalpha.com/article/4515224-wuxi-biologics-sporting-a-100x-forward-price-to-earnings-multiple Summary • We had previously owned WuXi Biologic shares but sold it in the second quarter of 2019. • We bought back WXIBF stock after a sharp price correction in the first quarter of 2021. • The rapid development of several antibody drugs for COVID-19 gave a further, unexpected boost to WuXi’s business recently. • WuXi’s share price tanked despite the positive surprise of an 83% year- over-year increase in revenue growth and a doubling of the company’s adjusted net profits. • Our read of WuXi’s sales growth has, if anything, proven too conservative in the near term, while its execution has been solid. ...

https://finance.sina.cn/hkstock/sckxjfx/2022-05-27/detail-imizmscu3643545.d.html?from=wap

https://finance.sina.cn/hkstock/sckxjfx/2022-05-26/detail-imizirau4855558.d.html?from=wap

http://www.aastocks.com/tc/stocks/news/aafn-con/rum.220526_114143/latest-news

https://www.benzinga.com/news/22/05/27334062/vir-biotechnology-shares-move-lower-co-wuxi-biologics-terminate-a-greater-china-collaboration-agreem

https://finance.sina.cn/hkstock/gsxw/2022-05-16/detail-imcwipik0201838.d.html?from=wap

https://www.defenseworld.net/2022/05/11/wuxi-biologics-cayman-inc-otcmktswxxwy-sees-large-drop-in-short-interest.html

https://finance.sina.cn/hkstock/sckxjfx/2022-05-11/detail-imcwipii9208257.d.html?from=wap

https://tw.stock.yahoo.com/news/%E7%BE%8E%E5%9C%8B%E5%88%B6%E8%A3%81%E4%B8%AD%E4%BC%81%E5%A0%B1%E5%B0%8E%E6%8C%AB%E5%82%B7%E9%A2%A8%E9%9A%AA%E6%83%85%E7%B7%92-%E4%B8%AD%E5%9C%8B-%E8%97%A5%E6%98%8E%E7%B3%BB-%E8%82%A1%E5%83%B9%E9%BD%8A%E8%B7%8C-032743592.html

https://finance.sina.cn/hkstock/sckxjfx/2022-05-05/detail-imcwipii8115898.d.html?from=wap

https://www.prnewswire.com/news-releases/wuxi-biologics-2021-esg-report-reveals-companys-strong-commitment-to-overall-sustainability-301534489.html

Austausch über kommunale China-Kooperation https://www.wuppertal.de/presse/meldungen/meldungen-2022/april/netzwerktreffen-china.php Beim zweiten interkommunalen Netzwerktreffen NRW mit Schwerpunkt China im Barmer Rathaus stand das kommunale China-Engagement im Fokus - im Spannungsfeld zwischen Werten und Interessen sowie Wirtschaft und Politik. ... China ist ein wichtiger Investor in NRW. Entgegen weitläufiger Meinungen handelt es sich dabei häufig um Neuansiedlungen und Erweiterungsinvestitionen und nicht nur um Übernahmen deutscher Unternehmen. Städte mit aktivem China-Engagement können laut Frank Weidtmann (NGB) diese Potenziale gewinnbringend nutzen. Für international tätige Unternehmen bleibt trotz anhaltender Lockdowns und einem schwieriger werdenden politischen Klima relevant, Wertschöpfungsketten zu lokalisieren und die Marktpräsenz zu steigern. Als Beispiel dient das Pharmaunternehmen WuXi Biologics, das vergangenes Jahr 185 Millionen Euro im Tal investiert hat. ...

Goldman flagged Morgan Stanley over HK block trades https://www.thestandard.com.hk/section-news/section/2/241014/Goldman-flagged-Morgan-Stanley-over-HK-block-trades Goldman Sachs reported Morgan Stanley to Hong Kong's financial regulator over a series of block trades by its rival three years ago, the Financial Times reported, citing people familiar with the matter. ... Trades including Wuxi Biologics Cayman (2269) stock are among those flagged and it's not clear whether the authorities investigated the claim by individuals at Goldman, according to the paper. ... Morgan Stanley executed nine block trade transactions for Wuxi between 2020 and 2021, the FT reported, citing Bloomberg data. There is no suggestion of wrongdoing by Wuxi. The Chinese company did not respond to the newspaper's request for comment.

http://www.aastocks.com/en/stocks/news/aafn-con/RUM.220421_135430/company-news